Evidence map›Paper›PMID 33061326›Full record

Observational studyClinical interventions in aging2020

Cerebral Thrombolysis in Rural Residents Aged ≥ 80.

Piotr Sobolewski, Waldemar Brola, Jacek Wilczyński, Wiktor Szczuchniak, Tomasz Wójcik, Aleksandra Wach-Klink, Marek Kos, Grzegorz Kozera

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Clinical interventions in aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Piotr SobolewskiCollegium Medicum, Jan Kochanowski University, Kielce, Poland.ORCID 0000-0003-4646-1702
Waldemar BrolaCollegium Medicum, Jan Kochanowski University, Kielce, Poland.ORCID 0000-0002-7955-3454
Jacek WilczyńskiCollegium Medicum, Jan Kochanowski University, Kielce, Poland.
Wiktor SzczuchniakDepartment of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Sandomierz, Poland.
Tomasz WójcikCollegium Medicum, Jan Kochanowski University, Kielce, Poland.ORCID 0000-0002-7647-6000
Aleksandra Wach-KlinkDepartment of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Sandomierz, Poland.
Marek KosDepartment of Neurology and Stroke Unit, Holy Spirit Specialist Hospital in Sandomierz, Sandomierz, Poland.
Grzegorz KozeraMedical Simulation Center, Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0001-7704-2434
Jan Kochanowski University · PLWyższa Szkoła Humanistyczno-Przyrodnicza w Sandomierzu · PLGdańsk Medical University · PLMedical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe proportion of older people in Poland is higher in rural areas than in urban areas. Thus, we aimed to evaluate treatment rate and factors associated with outcome and safety of intravenous thrombolysis (IVT) in rural residents aged ≥80 years admitted to primary stroke centers. PATIENTS AND

methodsThis study was a retrospective, observational cohort study of 873 patients treated with recombinant tissue plasminogen activator (rt-PA) in primary stroke centers between February 1, 2009 and December 31, 2017. Among them were 527 rural residents and 231 (26.5%) were ≥80 years of age. The analyses between rural and urban patients aged ≥80 and between rural patients aged <80 and aged ≥80 were performed.

resultsThe proportion of patients aged ≥80 treated with rt-PA was comparable in rural and urban residents (27.9% vs 24.3%

conclusionWe suggest that rural patients aged ≥80 may be safely treated with IVT in routine practice. However, lower efficacy and a higher mortality must be considered in former use of Vitamin K antagonist and antiplatelet or high white blood cells count.

Indexed as

Administration, IntravenousAged, 80 and overAge FactorsAnticoagulantsCerebral HemorrhageCohort StudiesComorbidityFemaleFibrinolytic AgentsHumansMalePhysical Functional PerformancePlatelet Aggregation InhibitorsPolandRetrospective StudiesRural PopulationAnticoagulantsFibrinolytic AgentsPlatelet Aggregation InhibitorsTissue Plasminogen Activatoratrial fibrillationintravenous thrombolysisischemic strokerural patients aged ≥ 80VKA

Identifiers

PMID33061326
PMCPMC7522422
OpenAlexW3087993899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.